XML 70 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investment in Subsidiaries - Additional Information (Detail) (USD $)
12 Months Ended 12 Months Ended
Sep. 30, 2013
Sep. 30, 2011
Sep. 30, 2010
Nov. 26, 2008
Sep. 30, 2013
Calando Pharmaceuticals Inc
Jun. 23, 2009
Calando Pharmaceuticals Inc
Nov. 26, 2008
Calando Pharmaceuticals Inc
Apr. 17, 2008
Calando Pharmaceuticals Inc
Sep. 30, 2011
Ablaris Therapeutics
Sep. 30, 2013
Ablaris Therapeutics
Sep. 30, 2013
Leonardo Biosystems, Inc.
Schedule Of Investments [Line Items]                      
Ownership percentage in subsidiary 100.00%                    
Aggregate investment in subsidiary through equity and debt               $ 23,200,000      
Unsecured Convertible Promissory Note Agreements       2,500,000     2,500,000        
Investment in Notes offering       200,000     200,000        
Additional investment in Notes offering             600,000        
Principal amount of note which not converted into shares           500,000          
Conversion of Notes and accrued interest into share           2,950          
Amount owed by subsidiary         4,300,000           1,100,000
Stated percentage of notes and advances         8.00%            
Percentage of outstanding shares         79.00%         64.00% 3.00%
Percentage of investment ownership         76.00%         64.00%  
Investment in preferred stock                 1,300,000    
Issuance of preferred stock in subsidiary   1,618,509 300,000           2,900,000    
Investment in preferred stock by outsider                 $ 1,600,000